<DOC>
	<DOCNO>NCT00126048</DOCNO>
	<brief_summary>Statins common type cholesterol-lowering drug use clinical practice . Recent research suggest may also anti-inflammatory property , particular inhibition important inflammatory cell call T lymphocyte . Asthma characterise chronic inflammation airway , think regulate activity T lymphocytes . The investigator find anti-inflammatory activity statin drug experimental model allergic asthma recently show beneficial effect statin , atorvastatin , patient rheumatoid arthritis . These finding demonstrate therapeutic potential statin-sensitive pathway allergic airway disease . The investigator plan perform `` proof concept '' study determine effectiveness statin therapy asthma . This randomise controlled trial test hypothesis statin improve asthma control patient chronic asthma . The study 22-week randomise controlled trial compare effect asthma control oral atorvastatin match placebo . Each treatment administer 8 week separate 6-week washout period . A total 52 allergic asthmatic patient recruit ensure 44 patient complete study . The investigator examine effect statin therapy lung function , symptom score , exacerbation rate , well measurement airway inflammation sputum blood . This study determine benefit atorvastatin add-on therapy asthma establish statin might role asthma management .</brief_summary>
	<brief_title>Trial Evaluate Effect Statins Asthma Control Patients With Chronic Asthma</brief_title>
	<detailed_description>Study Design : The study 24-week randomise double blind crossover study compare effect asthma control oral atorvastatin therapy ( 40 mg daily ) match placebo . Each treatment administer 8 week separate 6-week washout period 2-week run-in period prior randomisation . Randomisation perform sequential block . Patients assess 9 visit ( 13 occasion , visit perform 2 day ) : - Visit 1 : Screening visit : - Obtain write informed consent - General medical history &amp; physical examination - Complete asthma control questionnaire - Spirometry reversibility test . - Blood sampling ( 35 ml ) IgE serology , lipid , liver function test , creatinine kinase immunological test ( include sVCAM-1 , Sicam-1 , Spcam , E-selectin , CRP , MCP-1 , IL-6 , IL-10 TNF-alpha. ) . - Eligibility check - Issue diary card peak flow meter - Adjustment asthma medication BTS guideline require . Visit 2 : Baseline clinical measurements-2weeks visit 1 ( 4 week change make baseline asthma medication [ randomisation visit ] ) : - Complete asthma control questionnaire - Asthma Quality life questionnaire - ATS score assess severity asthma . - Spirometry reversibility test . - Induced sputum - Exhaled NO - Airway responsiveness methacholine - Randomise patient criterion meet . - Issue diary card Visits 3-9 2 , 4 , 8 , 14 , 16 , 18 &amp; 22 week randomisation : At study visit peak expiratory flow ( PEF ) diary retain spirometry perform . Patients record morning even PEF measurement daily symptom throughout study . Airway responsiveness methacholine , asthma control score , asthma quality life questionnaire , induced sputum , exhale NO blood sample immunological test , lipid liver function perform visit 5 , 6 9 . Pregnancy test perform woman child-bearing age visit 2 6 subject informed adequate contraception one month study . If subject find elevated lipid baseline , study would continue person referred appropriate specialist management study . If subject exacerbation wash-out phase study , visit 6 delayed patient stable 4 week . Anti-asthma drug treatment : Patients ask continue usual anti-asthma drug therapy throughout study . Measurements : Diary card recording : asthma symptom , PEF recording inhale beta2-agonist use . PEF measurement undertaken patient home use mini-Wright peak flow meter ( Clement Clarke , Harlow , UK ) . The best three measurement record twice daily ( pre-treatment ) diary . Peak flow variability calculate difference high low daily reading divide mean PEF reading multiply 100 ( amplitude % mean ) . The average 3 last 7 day PEF measurement visit use analysis . Exacerbations asthma : Mild exacerbation define one follow 2 consecutive day : drop peak flow &gt; 20 % baseline value , use 3 additional puff reliever bronchodilator 24 hour ( exclude prophylactic puff exercise ) compare baseline value night awaken due asthma . A severe exacerbation define worsen asthma control consider investigator general practitioner ( GP ) require short course oral corticosteroids/hospitalisation decrease morning peak flow 30 % baseline value 2 consecutive day . Other index disease severity relate asthma : Emergency/'out hour ' visit patient GP ; GP visit patient home ; GP investigator prescribe extra treatment ; Accident emergency ( A &amp; E ) department hospital attendance ; hospital admission length stay . Spirometry ( FEV1 , FVC ) , reversibility testing : Baseline pre-bronchodilator spirometric measurement record best three attempt use dry wedge spirometer ( Vitalograph , Buckingham , UK ) measurement vary 5 % 0.2ml . Spirometric measurement make nebulised salbutamol ( 2.5mg ) . Measurements perform time day ( pm ) patient . Total specific IgE : Total serum IgE IgE common allergen ( house dust mite , grass pollen cat dander ) measure enzyme immunoassay ( Unicap System , Pharmacia UK Ltd , Milton Keynes , UK ) . Total IgE &gt; 120 IU/L specific IgE &gt; 0.35 IU/L consider positive . Atopy define presence positive specific IgE common allergen . Airway responsiveness : Bronchial challenge test methacholine undertaken use Cockcroft 's technique concentration methacholine 0.03 16 mg. A value methacholine hyperreactivity &gt; 16 mg/ml read 16 mg/ml . Bronchial hyper-reactivity define PC20 FEV1 &lt; 8 mg/ml . Methacholine challenge test perform subject baseline FEV1 great 60 % predict . Induced sputum : An ultrasonic nebuliser fill 3 % saline subject inhale nebulised solution 7 minute follow pre-treatment inhaled salbutamol . After , nebuliser fill 4 % saline nebulised solution inhale 7 minute . Finally , nebuliser fill 5 % saline nebulised solution inhale 7 minute . At 5-minute interval inhalation stop allow expectoration polypropylene container . The sample keep ice process cell count ultra centrifugation harvest soluble phase sputum . Cell count perform supernatant store analysis inflammatory mediator . The test perform subject FEV1 &lt; 1 L. Measurement exhale NO : Exhaled NO measured chemiluminescence analyser ( LR2149 , Logan Research Ltd. , Rochester , Kent ) . The method use measure exhale NO comply ATS guideline . Allergen-driven lymphocyte proliferative response blood : Peripheral blood mononuclear cell ( 106 cells/ml ) culture autologous plasma 3 day ( mitogen anti-CD3/28 ) 7 day ( recombinant Der p1 allergen ) humidify atmosphere 37°C/5 % CO2 . Proliferation measure incorporation tritiated thymidine ( 0.5uCi ) 16hr harvest onto glass fibre filter count beta counter . Other immunological test blood : Luminex methodology cytokine release &amp; FACS technology co-stimulator molecule expression employ estimate alter cellular immune function whole blood culture time . Measurement lipid blood : Cholesterol , triglycerides HDL-cholesterol measure screen visit 5 , 6 9 . Serum biochemistry safety check : Blood renal function ( urea electrolyte ) liver function test ( LFT 's ) perform treatment period creatinine kinase perform baseline . Statistical Analysis : Power calculation : A sample size 44 90 % power detect difference mean 20L/min peak expiratory flow [ PEF ] ( primary endpoint ) , assume standard deviation difference 40L/min , use pair t-test 0.05 two-sided significance level . A total 52 patient recruited ensure 44 patient complete study . Data processing analysis : The primary analysis comparison treatment morning PEF . Secondary endpoint include : symptom score , exacerbation rate , spirometry , airway responsiveness methacholine , sputum cell count , eNO immunological test blood . The main analysis carry Normal Linear Models include parameter patient , period treatment . Some variable may unsuitable , case within-patient treatment difference calculate analysed either t-tests Wilcoxon test , appropriate .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Diagnosis asthma : This establish symptomatically episodic wheezing , chest tightness and/or dyspnoea objectively confirm methacholine airway hyperresponsiveness evidence variable airflow obstruction increase FEV1 &gt; 12 % follow nebulised salbutamol ( 2.5mg ) diurnal peak flow variability &gt; 20 % 3 day week ( minimum change 60 L ) runin period study ( BTS ) . Age range 1870 year Duration asthma &gt; 1 year stable medication 4 week Receiving regular inhaled steroid treatment ( ≤ 1000mcg Beclomethasone equivalent daily ) medication asthma shortacting bronchodilator . Symptomatic , define asthma control questionnaire score 1 ( range 06 ) prior randomisation use inhale beta2agonist 5 day week randomisation FEV1 reversibility &gt; 12 % diurnal peak flow variability &gt; 20 % runin period study least 3 day week . Stable asthma medication least 4 week prior randomisation Written inform consent Inability demonstrate correct use peak flow meter instruction Current smokers exsmokers &lt; 1 year exsmokers smoke &gt; 5 pack year . Patients unstable asthma , define presence 1 follow event month prior randomisation : *emergency/'out hour ' visit patient GP ; *GP visit patient home ; *A &amp; E hospital attendance ; *hospital admission . Patients cardiovascular risk require statin therapy Any known sensitivity adverse reaction statin , previous evidence myopathy myositis plus creatinine kinase liver function test &gt; x2 upper limit normal range . Nonatopic asthma ( specific IgE skin test negative common allergen ) [ skin test wheal &lt; /= 3mm negative control saline ] Patients show specific IgE sensitivity skin test positive grass pollen allergen recruit mid May end July ( grass allergen season United Kingdom [ UK ] ) . Pregnancy/lactation . Patients require medication know interact statin , azole antifungal agent , erythromycin , clarithromycin , cyclosporine , gemfibrozil , verapamil amiodarone . Inability fully comprehend patient information sheet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Atopy</keyword>
	<keyword>Statin</keyword>
	<keyword>Asthma</keyword>
	<keyword>methacholine</keyword>
	<keyword>FEV1</keyword>
</DOC>